NCT03258554 2026-02-06
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Phase 2/3 Completed
National Cancer Institute (NCI)
HiberCell, Inc.
University of Chicago
Eli Lilly and Company
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany